Alkem launches novel breast cancer treatment drug Palbociclib under brand name Palbo

Backed by in-house manufacturing, the launch of Palbo by Alkem endeavors to ensure the accessibility and affordability of a novel life-saving cancer drug for Indian breast cancer patients.

Palbo comes in capsule form in multiple dose strengths with varied pricing ranges, including 125mg at INR 6125/- for 21 capsules, 100mg at Rs. 6062/-, and 75mg at MRP Rs. 6000/- for 21 capsules.

“While this breast cancer drug is highly useful to patients, its reach in India is limited partly due to the high costs attached to the drug. We have now launched an affordable drug version backed by in-house production. We aim to make it easily accessible to the Indian population, ensuring availability at every pincode in the country.,” said Dr Akhilesh Sharma, President, and Chief Medical Officer, Alkem Laboratories Limited.

Palbociclib, a first-in-class CDK4/6 inhibitor which helps in inhibiting Cancer Cell growth and is used in combination with hormone therapies to treat hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer

Palbociclib alongwith AI & SERD (Fulvestrant) has been shown to significantly improve longevity among breast cancer patients, slow down the progression of disease, reduce cancer-related symptoms.

Alkem is a leading Indian Global paharmaceutical company that manufactures & markets biosmilars & pharmaceeutical formulations in India & across the globe.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Alkem Laboratories Limited.